PDB Short entry for 2MJV HEADER TRANSCRIPTION 16-JAN-14 2MJV TITLE SOLUTION STRUCTURES OF SECOND BROMODOMAIN OF BRD4 WITH DI-ACETYLATED TITLE 2 TWIST PEPTIDE COMPND MOL_ID: 1; COMPND 2 MOLECULE: TWIST-RELATED PROTEIN 1; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: PEPTIDE (UNP RESIDUES 68-79); COMPND 5 SYNONYM: CLASS A BASIC HELIX-LOOP-HELIX PROTEIN 38, BHLHA38, H-TWIST; COMPND 6 ENGINEERED: YES; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: BROMODOMAIN-CONTAINING PROTEIN 4; COMPND 9 CHAIN: B; COMPND 10 FRAGMENT: BROMODOMAIN 2 (UNP RESIDUES 333-460); COMPND 11 SYNONYM: BRD4, PROTEIN HUNK1; COMPND 12 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 MOL_ID: 2; SOURCE 3 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 4 ORGANISM_COMMON: HUMAN; SOURCE 5 ORGANISM_TAXID: 9606; SOURCE 6 GENE: BRD4, HUNK1 KEYWDS TUMORIGENESIS, TRANSCRIPTION EXPDTA SOLUTION NMR NUMMDL 20 AUTHOR L.ZENG,M.ZHOU REVDAT 2 15-NOV-23 2MJV 1 REMARK LINK ATOM REVDAT 1 19-MAR-14 2MJV 0 JRNL AUTH J.SHI,Y.WANG,L.ZENG,Y.WU,J.DENG,Q.ZHANG,Y.LIN,J.LI,T.KANG, JRNL AUTH 2 M.TAO,E.RUSINOVA,G.ZHANG,C.WANG,H.ZHU,J.YAO,Y.X.ZENG, JRNL AUTH 3 B.M.EVERS,M.M.ZHOU,B.P.ZHOU JRNL TITL DISRUPTING THE INTERACTION OF BRD4 WITH DIACETYLATED TWIST JRNL TITL 2 SUPPRESSES TUMORIGENESIS IN BASAL-LIKE BREAST CANCER. JRNL REF CANCER CELL V. 25 210 2014 JRNL REFN ISSN 1535-6108 JRNL PMID 24525235 JRNL DOI 10.1016/J.CCR.2014.01.028 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : ARIA 2.2, CNS REMARK 3 AUTHORS : LINGE, O'DONOGHUE AND NILGES (ARIA), BRUNGER, REMARK 3 ADAMS, CLORE, GROS, NILGES AND READ (CNS) REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2MJV COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 28-JAN-14. REMARK 100 THE DEPOSITION ID IS D_1000103700. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 298 REMARK 210 PH : 6.5 REMARK 210 IONIC STRENGTH : NULL REMARK 210 PRESSURE : AMBIENT REMARK 210 SAMPLE CONTENTS : 5 MM [U-100% 2H] DTT, 100 MM REMARK 210 SODIUM PHOSPHATE, 100% D2O; 5 MM REMARK 210 [U-100% 2H] DTT, 100 MM SODIUM REMARK 210 PHOSPHATE, 90% H2O/10% D2O REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 3D HNCACB; 3D HN(COCA)CB; 3D 1H REMARK 210 -15N NOESY; 3D 1H-15N TOCSY; 3D REMARK 210 1H-13C NOESY ALIPHATIC; 3D 1H- REMARK 210 13C NOESY AROMATIC; 3D 13C- REMARK 210 EDITED 13C/15N-FILTERED NOESY REMARK 210 AROMATIC; 3D 13C-EDITED 13C/15N- REMARK 210 FILTERED NOESY ALIPHATIC REMARK 210 SPECTROMETER FIELD STRENGTH : 900 MHZ; 800 MHZ; 700 MHZ; 600 REMARK 210 MHZ REMARK 210 SPECTROMETER MODEL : AVANCE REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : NMRPIPE 7.1, NMRVIEW 5.04, CNS REMARK 210 1.2, TOPSPIN 1.3 REMARK 210 METHOD USED : SIMULATED ANNEALING, DGSA REMARK 210 -DISTANCE GEOMETRY SIMULATED REMARK 210 ANNEALING REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 200 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 20 REMARK 210 CONFORMERS, SELECTION CRITERIA : STRUCTURES WITH THE LOWEST REMARK 210 ENERGY REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: NULL REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O LEU B 354 HG CYS B 357 1.54 REMARK 500 O GLN B 353 H CYS B 357 1.55 REMARK 500 O TYR B 390 H ILE B 394 1.56 REMARK 500 O CYS B 429 HD21 ASN B 433 1.59 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 1 ALY A 6 -63.71 28.21 REMARK 500 1 ALY A 9 144.40 63.18 REMARK 500 1 LYS A 10 21.27 -143.63 REMARK 500 1 SER A 11 -38.27 74.45 REMARK 500 1 ASP B 334 73.74 57.52 REMARK 500 1 VAL B 335 125.85 71.48 REMARK 500 1 GLN B 340 -35.18 -157.29 REMARK 500 1 GLU B 345 -73.16 65.34 REMARK 500 1 LYS B 346 -55.10 -144.31 REMARK 500 1 SER B 347 -98.00 -125.49 REMARK 500 1 SER B 348 -37.36 70.86 REMARK 500 1 TYR B 372 -8.60 -150.28 REMARK 500 1 HIS B 388 -60.05 69.31 REMARK 500 1 PRO B 458 -172.46 -69.51 REMARK 500 1 ASP B 459 1.75 -165.85 REMARK 500 2 PRO A 2 57.39 -97.55 REMARK 500 2 ALA A 3 -81.73 -88.22 REMARK 500 2 GLN A 4 -9.64 168.47 REMARK 500 2 ALY A 6 -42.39 146.36 REMARK 500 2 ARG A 7 9.34 59.15 REMARK 500 2 ALY A 9 154.40 77.08 REMARK 500 2 LYS A 10 36.81 -162.43 REMARK 500 2 SER B 338 -60.91 -90.30 REMARK 500 2 PRO B 342 -165.73 -63.98 REMARK 500 2 PRO B 344 -111.14 -92.95 REMARK 500 2 LYS B 346 -68.08 -137.51 REMARK 500 2 SER B 347 -86.95 -108.40 REMARK 500 2 SER B 348 -36.29 61.64 REMARK 500 2 TYR B 372 -8.98 -150.92 REMARK 500 2 HIS B 396 77.70 -155.57 REMARK 500 3 ALY A 6 -44.25 150.08 REMARK 500 3 ALY A 9 155.95 63.45 REMARK 500 3 ASP B 334 58.13 -93.93 REMARK 500 3 PRO B 336 107.63 -55.95 REMARK 500 3 SER B 338 71.18 -108.04 REMARK 500 3 PRO B 344 -78.38 -54.10 REMARK 500 3 LYS B 346 -56.09 -164.44 REMARK 500 3 SER B 347 -94.58 -118.09 REMARK 500 3 SER B 348 -37.40 69.40 REMARK 500 3 TYR B 372 -7.99 -152.11 REMARK 500 3 ARG B 410 17.51 56.04 REMARK 500 3 PRO B 458 -158.48 -67.03 REMARK 500 3 ASP B 459 -16.11 -176.81 REMARK 500 4 ALA A 3 -85.89 -109.70 REMARK 500 4 GLN A 4 -27.07 178.84 REMARK 500 4 ALY A 6 -59.06 29.40 REMARK 500 4 ALY A 9 147.49 64.18 REMARK 500 4 ASP B 337 -62.50 72.31 REMARK 500 4 LYS B 346 -59.63 -143.35 REMARK 500 4 SER B 348 -36.33 156.63 REMARK 500 REMARK 500 THIS ENTRY HAS 279 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 LYS B 349 VAL B 350 6 -149.96 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN A OF TWIST-RELATED REMARK 800 PROTEIN 1 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 19738 RELATED DB: BMRB DBREF 2MJV A 1 12 UNP Q15672 TWST1_HUMAN 68 79 DBREF 2MJV B 333 460 UNP O60885 BRD4_HUMAN 333 460 SEQRES 1 A 12 SER PRO ALA GLN GLY ALY ARG GLY ALY LYS SER ALA SEQRES 1 B 128 LYS ASP VAL PRO ASP SER GLN GLN HIS PRO ALA PRO GLU SEQRES 2 B 128 LYS SER SER LYS VAL SER GLU GLN LEU LYS CYS CYS SER SEQRES 3 B 128 GLY ILE LEU LYS GLU MET PHE ALA LYS LYS HIS ALA ALA SEQRES 4 B 128 TYR ALA TRP PRO PHE TYR LYS PRO VAL ASP VAL GLU ALA SEQRES 5 B 128 LEU GLY LEU HIS ASP TYR CYS ASP ILE ILE LYS HIS PRO SEQRES 6 B 128 MET ASP MET SER THR ILE LYS SER LYS LEU GLU ALA ARG SEQRES 7 B 128 GLU TYR ARG ASP ALA GLN GLU PHE GLY ALA ASP VAL ARG SEQRES 8 B 128 LEU MET PHE SER ASN CYS TYR LYS TYR ASN PRO PRO ASP SEQRES 9 B 128 HIS GLU VAL VAL ALA MET ALA ARG LYS LEU GLN ASP VAL SEQRES 10 B 128 PHE GLU MET ARG PHE ALA LYS MET PRO ASP GLU MODRES 2MJV ALY A 6 LYS N(6)-ACETYLLYSINE MODRES 2MJV ALY A 9 LYS N(6)-ACETYLLYSINE HET ALY A 6 26 HET ALY A 9 26 HETNAM ALY N(6)-ACETYLLYSINE FORMUL 1 ALY 2(C8 H16 N2 O3) HELIX 1 1 LYS B 349 PHE B 365 1 17 HELIX 2 2 ALA B 373 LYS B 378 1 6 HELIX 3 3 ASP B 389 ILE B 394 1 6 HELIX 4 4 ASP B 399 GLU B 408 1 10 HELIX 5 5 ASP B 414 ASN B 433 1 20 HELIX 6 6 HIS B 437 LYS B 456 1 20 LINK C GLY A 5 N ALY A 6 1555 1555 1.34 LINK C ALY A 6 N ARG A 7 1555 1555 1.34 LINK C GLY A 8 N ALY A 9 1555 1555 1.34 LINK C ALY A 9 N LYS A 10 1555 1555 1.32 SITE 1 AC1 21 ALA B 371 TRP B 374 PRO B 375 PHE B 376 SITE 2 AC1 21 PRO B 379 VAL B 380 ASP B 381 LEU B 385 SITE 3 AC1 21 LEU B 387 ASP B 389 ILE B 393 ASN B 428 SITE 4 AC1 21 CYS B 429 LYS B 431 TYR B 432 ASN B 433 SITE 5 AC1 21 PRO B 434 HIS B 437 GLU B 438 VAL B 439 SITE 6 AC1 21 MET B 442 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000